DATASET 2026-08-0941 PROGRAMS INDEXEDTIRZEPATIDE ALL-IN $215–$597/MOEVERY FIGURE CAPTURE-DATED & SOURCE-LINKED
TopGLP1Providers.comverified price index
VERIFIED 2026-08-09
NexLife T $215✓Yucca Health T $258✓IVIM Health T $278✓Mochi Health T $278✓ShedRx T $289✓Found T $289✓SkinnyRx T $299✓OrderlyMeds T $299✓Amble Health T $300✓Henry Meds T $349✓TrimRx T $349✓Lavender Sky Health T $352✓Fridays T $359✓MEDVi T $399✓Remedy Meds T $399✓Eden T $408✓LifeMD T $597✓Oak Longevity S $133✓Yucca Health S $146✓IVIM Health S $149✓OrderlyMeds S $149✓NexLife S $165✓Lavender Sky Health S $174✓Zepbound vials $449✓Wegovy $349✓Oral Wegovy from $149✓NexLife T $215✓Yucca Health T $258✓IVIM Health T $278✓Mochi Health T $278✓ShedRx T $289✓Found T $289✓SkinnyRx T $299✓OrderlyMeds T $299✓Amble Health T $300✓Henry Meds T $349✓TrimRx T $349✓Lavender Sky Health T $352✓Fridays T $359✓MEDVi T $399✓Remedy Meds T $399✓Eden T $408✓LifeMD T $597✓Oak Longevity S $133✓Yucca Health S $146✓IVIM Health S $149✓OrderlyMeds S $149✓NexLife S $165✓Lavender Sky Health S $174✓Zepbound vials $449✓Wegovy $349✓Oral Wegovy from $149✓

2026-08-10 · BOTH · TopGLP1Providers Data Desk

The brand price collapse, dated: 2023–2026

In three years, the cash price of brand GLP-1s fell from four figures a month to $299–$449 for Zepbound vials and $349 for Wegovy — a collapse driven by compounding competition, political pressure, and the manufacturers’ discovery that direct-to-consumer channels beat list-price fictions. Each cut re-priced the compounded market’s reason to exist, and the sequence explains today’s numbers better than any single price tag.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

2023: the four-figure era. Wegovy and Zepbound launched into US list prices in the $1,000–$1,350/month range, coverage was scarce, and the gap between list and the earliest compounded programs (then commonly $200–$400) created the largest arbitrage consumer medicine had seen in years. The compounding boom of 2023–2024 was that gap wearing a telehealth interface. 2024: the first direct channels. Lilly’s LillyDirect↗ launched with Zepbound single-dose vials for cash payers — initially $399 and $549 tiers, later $349–$499 — the first acknowledgment that a manufacturer would compete on cash price rather than cede the uninsured market. Novo followed with NovoCare↗ pricing Wegovy at $499 cash. Meanwhile the FDA declared the tirzepatide shortage resolved (October, reaffirmed December 2024), starting the legal clock on mass compounding.

2025: the squeeze from both sides. Enforcement discretion for compounded copies expired on a staggered schedule (February–May 2025 across molecules and pharmacy classes), and a federal court upheld the FDA in May — shrinking the compounded market’s legal footprint precisely as brand prices kept falling. By late 2025 the political theater around drug pricing produced concrete numbers: commitments to bring popular GLP-1 cash prices toward $245–$350 through direct channels, and on December 1, 2025, Lilly cut Zepbound vials to $299 (2.5 mg), $399 (5 mg), and $449 (7.5–15 mg) — with the maintenance rate conditional on refilling inside a 45-day window, a loyalty mechanic disguised as a price. January 5, 2026: Novo launched the oral Wegovy pill at $149–$299 and held injectable Wegovy at $349 standard with a $199 two-month intro — the first time an approved GLP-1 undercut most compounded programs outright.

What the collapse did to the comparison. Every brand cut mechanically shrank the compounded discount that justified the category. Today the gap at maintenance is $234/month on tirzepatide (Zepbound $449 vs the $215 verified floor) and as little as $203/month on broadly available semaglutide — real money, but no longer a different universe, and on semaglutide arguably inside the value of FDA manufacturing oversight. The strategic reading for a buyer in 2026: brand prices have fallen on a schedule and may fall again (orforglipron and further oral competition are priced into every forecast), so long prepaid commitments to any cash program — compounded or brand — carry a new risk the 2023 market never had: the risk that the price you locked becomes the price everyone else stopped paying. The lane-by-lane comparison lives in the Zepbound analysis and the Wegovy analysis; the current floors, always, in the database.

Historical prices reflect public announcements at the dates shown; current figures captured 2026-08-09.

The cheapest compounded tirzepatide online rigThe cheapest compounded semaglutide online, inCompounded tirzepatide vs ZepboundWhat a year of tirzepatide actually costs, proDose-flat vs dose-tiered pricing